title: Pityriasis rubra pilaris types 1 and 2: different responses to treatment with TNF-alpha antagonists.
authors.affiliation: Department of Dermatology, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria, Department of Dermatology, Mount Zion Cancer Research Center, San Francisco, CA 94115, USA.
authors.forename: Igor
authors.initials: I
authors.lastname: Vujic
authors.affiliation: Department of Dermatology, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria.
authors.forename: Leo
authors.initials: L
authors.lastname: Richter
authors.affiliation: Department of Dermatology, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria.
authors.forename: Katrin
authors.initials: K
authors.lastname: Bartsch
authors.affiliation: Department of Dermatology, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria.
authors.forename: Babak
authors.initials: B
authors.lastname: Monshi
authors.affiliation: Department of Dermatology, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria.
authors.forename: Klemens
authors.initials: K
authors.lastname: Rappersberger
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D057915:Drug Substitution; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D010916:Pityriasis Rubra Pilaris / Q000145:classification / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept